New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
14:43 EDTILMN, AMGNIllumina February volatility up, shares at record high on agreement with Amgen
Illumina (ILMN) February call option implied volatility is at 40, March is at 36, June is at 35; compared to its 26-week average of 35 according to Track Data, suggesting large near term price movement on an agreement with Amgen (AMGN) to develop oncology companion diagnostic test.
News For ILMN;AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 20, 2014
16:13 EDTILMNIllumina trades higher after results, first look
Subscribe for More Information
16:11 EDTILMNIllumina raises FY14 EPS view to $2.63-$2.65, consensus $2.30
Raises FY14 revenue growth view to approximately 30% YoY, consensus $1.8B. Prior view was $2.26-$2.28 for EPS and 25%-26% for revenue growth. Cites strong year to date results.
16:09 EDTILMNIllumina reports Q3 gross margin 69.5% vs. 58.8% in prior year period
Subscribe for More Information
16:09 EDTILMNIllumina reports Q3 adjusted EPS 77c, consensus 56c
Subscribe for More Information
15:30 EDTILMNNotable companies reporting after market close
Subscribe for More Information
07:19 EDTAMGNIBC Life Sciences to hold a conference
Subscribe for More Information
07:11 EDTILMNAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTILMNAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 19, 2014
15:56 EDTAMGNAmgen to aid in production method for Ebola drug ZMapp, Bloomberg says
Subscribe for More Information
October 17, 2014
09:06 EDTAMGNAmgen files patent infringement lawsuit against Sanofi, Regeneron
Amgen (AMGN) announced that it filed a lawsuit in the United States District Court of Delaware against Sanofi (SNY), Aventisub, formerly doing business as Aventis Pharmaceuticals, and Regeneron Pharmaceuticals (REGN) for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned by Amgen, describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, or PCSK9. By its complaint, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced that they have completed Phase 3 clinical trials on alirocumab and intend to pursue regulatory approval to market alirocumab in the U.S. Amgen previously announced submission of a Biologics License Application to the FDA for evolocumab, its own investigational human monoclonal antibody to PCSK9, for the treatment of high cholesterol, on Aug. 28.
October 16, 2014
10:01 EDTILMNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
05:33 EDTILMNIllumina upgraded to Overweight from Neutral at Piper Jaffray
Subscribe for More Information
October 15, 2014
06:32 EDTILMNIllumina to invest in three genomics industry startups
Illumina selected three startup companies for the inaugural Illumina Accelerator funding cycle. The companies are Encoded Genomics, EpiBiome and Xcell Biosciences. The Illumina Accelerator will provide selected startups with seed investment, business guidance, access to Illumina’s sequencing systems and reagents, and fully operational lab space in the San Francisco Bay Area during the six-month cycle.
October 14, 2014
11:23 EDTAMGNBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
08:15 EDTILMNIllumina should report stronger than expected results, says Wedbush
Subscribe for More Information
October 9, 2014
16:11 EDTAMGNAmgen blinatumomab granted priority review by FDA
Subscribe for More Information
October 8, 2014
10:20 EDTAMGNAmgen biosimilar franchise underappreciated, says Piper Jaffray
After Amgen announced positive Phase 3 results for its biosimilar Humira in psoriasis, Piper Jaffray said it believes that Amgen's overall pipeline is underappreciated since the company's biosimilar franchise is generally not included in consensus estimates. The firm views Amgen as a top large cap picks and reiterate its Overweight rating on the stock.
09:16 EDTAMGNAmgen's ABP 501 for psoriasis shows positive Phase 3 results
Subscribe for More Information
07:19 EDTAMGNCBI to hold a conference
Subscribe for More Information
07:11 EDTAMGNEuropean Academy of Dermatology and Venereology to hold a conference
23rd EADV Congress is being held in Amsterdam, The Netherlands on October 8-12.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use